These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31583094)

  • 1. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure.
    Caltabiano S; Cizman B; Burns O; Mahar KM; Johnson BM; Ramanjineyulu B; Serbest G; Cobitz AR
    Clin Kidney J; 2019 Oct; 12(5):693-701. PubMed ID: 31583094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis.
    Bailey CK; Caltabiano S; Cobitz AR; Huang C; Mahar KM; Patel VV
    BMC Nephrol; 2019 Oct; 20(1):372. PubMed ID: 31619187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
    Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
    Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
    Groenendaal-van de Meent D; Kerbusch V; Kaspera R; Barroso-Fernandez B; Galletti P; Klein GK; den Adel M
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):141-153. PubMed ID: 33165773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia.
    Mahar KM; Yang S; Mesic E; Post TM; Goulooze SC
    Clin Pharmacokinet; 2024 Sep; 63(9):1327-1341. PubMed ID: 39259485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects.
    Cizman B; Sykes AP; Paul G; Zeig S; Cobitz AR
    Kidney Int Rep; 2018 Jul; 3(4):841-850. PubMed ID: 29989040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease.
    Johnson HN; Prasad-Reddy L
    Ann Pharmacother; 2025 Jan; 59(1):71-80. PubMed ID: 38616529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease.
    Holdstock L; Cizman B; Meadowcroft AM; Biswas N; Johnson BM; Jones D; Kim SG; Zeig S; Lepore JJ; Cobitz AR
    Clin Kidney J; 2019 Feb; 12(1):129-138. PubMed ID: 30746140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis.
    Meadowcroft AM; Cizman B; Holdstock L; Biswas N; Johnson BM; Jones D; Nossuli AK; Lepore JJ; Aarup M; Cobitz AR
    Clin Kidney J; 2019 Feb; 12(1):139-148. PubMed ID: 30746141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Daprodustat Vs rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis.
    Fu Z; Geng X; Chi K; Song C; Wu D; Liu C; Hong Q
    Front Pharmacol; 2022; 13():746265. PubMed ID: 35359863
    [No Abstract]   [Full Text] [Related]  

  • 11. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: a meta-analysis of randomized clinical trials.
    Fatima K; Ahmed W; Fatimi AS; Mahmud O; Mahar MU; Ali A; Aamir SR; Nasim MT; Islam MB; Maniya MT; Azim D; Marsia S; Almas T
    Eur J Clin Pharmacol; 2022 Dec; 78(12):1867-1875. PubMed ID: 36195739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial.
    Nangaku M; Hamano T; Akizawa T; Tsubakihara Y; Nagai R; Okuda N; Kurata K; Nagakubo T; Jones NP; Endo Y; Cobitz AR
    Am J Nephrol; 2021; 52(1):26-35. PubMed ID: 33561857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease.
    Gan L; Xie P; Tan Y; Wei G; Yuan X; Lu Z; Pratt R; Zhou Y; Hui AM; Li K; Fang Y; Zuo L
    Drugs R D; 2022 Jun; 22(2):119-129. PubMed ID: 35380419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations.
    Sackeyfio A; Lopes RD; Kovesdy CP; Cases A; Mallett SA; Ballew N; Keeley TJ; Garcia-Horton V; Ayyagari R; Camejo RR; Johansen KL; Sutton AJ; Dasgupta I
    Clin Kidney J; 2024 Jan; 17(1):sfad298. PubMed ID: 38250252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
    Zheng Q; Wang Y; Yang H; Sun L; Fu X; Wei R; Liu YN; Liu WJ
    Front Pharmacol; 2020; 11():573645. PubMed ID: 33597868
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of daprodustat for patients on dialysis with anemia: systematic review and network meta-analysis.
    Ali Fadlalmola H; Al-Sayaghi KM; Al-Hebshi AA; Alhujaily M; Alyamani AO; Alem AA; Syrafi MH; Alem S; Farhat AH; Mohamed FA; Abdalrahman HH; Abdelmalik MA; Abdalrhman NM; Eltayeb AM
    Pan Afr Med J; 2024; 47():114. PubMed ID: 38828426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function.
    Mahar KM; Shaddinger BC; Ramanjineyulu B; Andrews S; Caltabiano S; Lindsay AC; Cobitz AR
    Clin Pharmacol Drug Dev; 2022 May; 11(5):562-575. PubMed ID: 35355447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.
    Besarab A; Chernyavskaya E; Motylev I; Shutov E; Kumbar LM; Gurevich K; Chan DT; Leong R; Poole L; Zhong M; Saikali KG; Franco M; Hemmerich S; Yu KH; Neff TB
    J Am Soc Nephrol; 2016 Apr; 27(4):1225-33. PubMed ID: 26494833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.